Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 May 28;15(6):9519-30.
doi: 10.3390/ijms15069519.

Molecular biology of brain metastasis

Affiliations
Review

Molecular biology of brain metastasis

Konstantina A Svokos et al. Int J Mol Sci. .

Abstract

Metastasis to the central nervous system (CNS) remains a major cause of morbidity and mortality in patients with systemic cancer. As the length of survival in patients with systemic cancer improves, thanks to multimodality therapies, focusing on metastases to the CNS becomes of paramount importance. Unique interactions between the brain's micro-environment, blood-brain barrier, and tumor cells are hypothesized to promote distinct molecular features in CNS metastases that may require tailored therapeutic approaches. This review will focus on the pathophysiology, epigenetics, and immunobiology of brain metastases in order to understand the metastatic cascade. Cancer cells escape the primary tumor, intravasate into blood vessels, survive the hematogenous dissemination to the CNS, arrest in brain capillaries, extravasate, proliferate, and develop angiogenic abilities to establish metastases. Molecular biology, genetics, and epigenetics are rapidly expanding, enabling us to advance our knowledge of the underlying mechanisms involved. Research approaches using cell lines that preferentially metastasize in vivo to the brain and in vitro tissue-based studies unfold new molecular leads into the disease. It is important to identify and understand the molecular pathways of the metastatic cascade in order to target the investigation and development of more effective therapies and research directions.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overview of cancer cell interactions with stromal and immune cells, genetic and epigenetic changes during the metastatic cascade.

References

    1. Barnholtz-Sloan J.S., Sloan A.E., Davis F.G., Vigneau F.D., Lai P., Sawaya R.E. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan detroit cancer surveillance system. J. Clin. Oncol. 2004;22:2865–2872. doi: 10.1200/JCO.2004.12.149. - DOI - PubMed
    1. McDermott R., Gabikian P., Sarvaiya P., Ulasov I., Lesniak M.S. Micrornas in brain metastases: Big things come in small packages. J. Mol. Med. 2013;91:5–13. doi: 10.1007/s00109-012-0971-3. - DOI - PubMed
    1. Barajas R.F., Jr., Cha S. Imaging diagnosis of brain metastasis. Prog. Neurol. Surg. 2012;25:55–73. doi: 10.1159/000331174. - DOI - PubMed
    1. Delattre J.Y., Krol G., Thaler H.T., Posner J.B. Distribution of brain metastases. Arch. Neurol. 1988;45:741–744. doi: 10.1001/archneur.1988.00520310047016. - DOI - PubMed
    1. Chang E.L., Wefel J.S., Maor M.H., Hassenbusch S.J., 3rd, Mahajan A., Lang F.F., Woo S.Y., Mathews L.A., Allen P.K., Shiu A.S., et al. A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone. Neurosurgery. 2007;60:277–283. - PubMed